Literature DB >> 13844822

Studies on fractions of methanol extracts of tubercle bacilli. I. Fractions which increase resistance to infection.

C A WILLIAMS, R J DUBOS.   

Abstract

Fractionation procedures yielding partially purified vaccine preparations from a 60 degrees C. methanol extract of tubercle bacilli have been described. Some of the preparations have the characteristics of lipopolysaccharides. Certain ones have been found capable of increasing resistance to experimental tuberculosis in albino mice of the Rockefeller Swiss strain. The levels of resistance elicited by these preparations are equivalent to those following vaccination with BCG (Phipps) in this strain of mice as reported by other authors. The admixture of two of the crude fractions in amounts as small as 0.05 mg. each per dose per mouse affords an even greater increase in resistance. Neither of these substances alone in larger doses can approach this degree of efficacy in mouse protection experiments. The protective activity appears to involve the stimulation of two supplementary mechanisms, one providing a peak resistance between 1 and 3 weeks post vaccination but falling off to a lower level thereafter, the other not responding fully until approximately 6 weeks but continuing undiminished through a 12 week post-vaccination period. The first of these peaks corresponds to an increase in resistance against staphylococci as well as tubercle bacilli. The possibility that the term "broad specificity," rather than "non-specificity," might best describe this phenomenon permits the implication of classical immune mechanisms.

Entities:  

Keywords:  MYCOBACTERIUM TUBERCULOSIS/chemistry

Mesh:

Substances:

Year:  1959        PMID: 13844822      PMCID: PMC2137037          DOI: 10.1084/jem.110.6.981

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  Viability and multiplication of vaccines in immunization against tuberculosis.

Authors:  H BLOCH; W SEGAL
Journal:  Am Rev Tuberc       Date:  1955-02

2.  The effectiveness of tuberculo-glycolipid as an adjuvant in eliciting allergic encephalomyelitis and aspermatogenesis.

Authors:  J FREUND; S H STONE
Journal:  J Immunol       Date:  1959-06       Impact factor: 5.422

3.  [Test of mouse protection as a criterion of BCG activity].

Authors:  F M LEVY; G CONGE
Journal:  Rev Immunol Ther Antimicrob       Date:  1955

4.  The role of various chemical fractions of M. tuberculosis and other Mycobacteria in the production of allergic encephalomyelitis.

Authors:  R G WHITE; A H MARSHALL
Journal:  Immunology       Date:  1958-04       Impact factor: 7.397

5.  Demonstration of differences between normal and tumor-bearing animals.

Authors:  V RILEY
Journal:  Proc Soc Exp Biol Med       Date:  1958-01

6.  Experimental sensitization with particular reference to picryl chloride.

Authors:  M W CHASE
Journal:  Int Arch Allergy Appl Immunol       Date:  1954

7.  The effect of bacterial constituents on the resistance of mice to heterologous infection and on the activity of their reticulo-endothelial system.

Authors:  D BOEHME; R J DUBOS
Journal:  J Exp Med       Date:  1958-04-01       Impact factor: 14.307

8.  Increased resistance to infection and accompanying alteration in properidin levels following administration of bacterial lipopolysaccharides.

Authors:  M LANDY; L PILLEMER
Journal:  J Exp Med       Date:  1956-09-01       Impact factor: 14.307

9.  Studies on tubercle bacillus-monocyte relationship. I. Quantitative analysis of effect of serum of animals vaccinated with BCG upon bacterium-monocyte system.

Authors:  S S ELBERG; J FONG; P SCHNEIDER
Journal:  J Exp Med       Date:  1956-10-01       Impact factor: 14.307

10.  Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections I. Protective effects.

Authors:  R J DUBOS; R W SCHAEDLER
Journal:  J Exp Med       Date:  1957-11-01       Impact factor: 14.307

View more
  11 in total

1.  Isolation of a Soluble Resistance-Enhancing Factor from Mycobacterium phlei.

Authors:  A E Fox; J Anschel; G L Evans; R R Mohan; B S Schwartz
Journal:  J Bacteriol       Date:  1966-08       Impact factor: 3.490

2.  Stimulation of nonspecific resistance to infection by a crude cell wall preparation from Mycobacterium phlei.

Authors:  A E Fox; G L Evans; F J Turner; B S Schwartz; A Blaustein
Journal:  J Bacteriol       Date:  1966-07       Impact factor: 3.490

3.  Enhancement of resistance to murine osteogenic sarcoma in vivo by an extract of Brucella abortus (Bru-Pel): association with activation of reticuloendothelial system macrophages.

Authors:  L A Glasgow; J L Crane; C J Schleupner; E R Kern; J S Youngner; D S Feingold
Journal:  Infect Immun       Date:  1979-01       Impact factor: 3.441

4.  RESISTANCE-ENHANCING ACTIVITY OF CULTURE FILTRATES OF MYCOBACTERIUM TUBERCULOSIS.

Authors:  L W HEDGECOCK
Journal:  J Bacteriol       Date:  1964-11       Impact factor: 3.490

5.  Fate of tubercle bacilli in lipopoly-saccharide- and BCG-treated mice.

Authors:  I KOCHAN; S R ROSE
Journal:  J Bacteriol       Date:  1962-08       Impact factor: 3.490

6.  Nonspecific factors in resistance of mice to experimental tuberculosis.

Authors:  G P Youmans; A S Youmans
Journal:  J Bacteriol       Date:  1965-12       Impact factor: 3.490

7.  Susceptibility of rabbits immunized with Mycobacterium bovis (BCG) or Mycobacterium phlei to Shigella keratoconjunctivitis.

Authors:  M Nakamura; W R Cross
Journal:  Infect Immun       Date:  1972-12       Impact factor: 3.441

8.  Specificity of acquired resistance produced by immunization with mycobacterial cells and mycobacterial fractions.

Authors:  S Coppel; G P Youmans
Journal:  J Bacteriol       Date:  1969-01       Impact factor: 3.490

9.  The susceptibility of mice to bacterial endotoxins.

Authors:  R W SCHAEDLER; R J DUBOS
Journal:  J Exp Med       Date:  1961-03-01       Impact factor: 14.307

10.  STUDIES ON THE HETEROLOGOUS IMMUNOGENICITY OF A MENTHANOL-INSOLUBLE FRACTION OF ATTENUATED TUBERCLE BACILLI (BCG). I. ANTIMICROBIAL PROTECTION.

Authors:  D W WEISS; R S BONHAG; J A PARKS
Journal:  J Exp Med       Date:  1964-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.